-
Full Article (HTML) (103) -
Full Article (PDF) (36) -
Send to Friends (0)
Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2249)
All Articles published online
|
Dec 14, 2010 (publication date) through Oct 19, 2021
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: |
Li FH, Shen L, Li ZH, Luo HY, Qiu MZ, Zhang HZ, Li YH, Xu RH. Impact of |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v16/i46/5881.htm |
| Number | Citing Articles |
| 1 |
Brigette B Ma, Frankie Mo, Joanna H Tong, Ashley Wong, SC Cesar Wong, Wing M Ho, Cherry Wu, Polly WY Lam, KF Chan, Timothy SK Chan, Wilson MS Tsui, Alex KH Tsang, Mandy NS Fung, Anthony TC Chan, Ka Fai To. Elucidating the prognostic significance ofKRAS,NRAS,BRAFandPIK3CAmutations in Chinese patients with metastatic colorectal cancer. Asia-Pacific Journal of Clinical Oncology 2015; 11(2): 160 doi: 10.1111/ajco.12342
|
| 2 |
Precision Oncology—The Quest for Evidence. Journal of Personalized Medicine 2019; 9(3): 43 doi: 10.3390/jpm9030043
|
| 3 |
B.A. Bohn, S. Mina, A. Krohn, R. Simon, M. Kluth, S. Harasimowicz, A. Quaas, M. Bockhorn, J.R. Izbicki, G. Sauter, A. Marx, P.R. Stahl. Altered PTEN function caused by deletion or gene disruption is associated with poor prognosis in rectal but not in colon cancer. Human Pathology 2013; 44(8): 1524 doi: 10.1016/j.humpath.2012.12.006
|
| 4 |
LEE CHENG PHUA, HUI WEN NG, ANGIE HUI LING YEO, ELYA CHEN, MICHELLE SHU MEI LO, PEH YEAN CHEAH, ERIC CHUN YONG CHAN, POH KOON KOH, HAN KIAT HO. Prevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancer. Oncology Letters 2015; 10(4): 2519 doi: 10.3892/ol.2015.3560
|
| 5 |
Zain A Sobani, Ashwin Sawant, Mikram Jafri, Amit Keith Correa, Ibrahim Halil Sahin. Oncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancer. World Journal of Clinical Oncology 2016; 7(5): 340-351 doi: 10.5306/wjco.v7.i5.340
|
| 6 |
Amartej Merla, Sanjay Goel. Novel Drugs Targeting the Epidermal Growth Factor Receptor and Its Downstream Pathways in the Treatment of Colorectal Cancer: A Systematic Review. Chemotherapy Research and Practice 2012; 2012: 1 doi: 10.1155/2012/387172
|
| 7 |
Jing Gao, Ting-ting Wang, Jing-wei Yu, Yan-yan Li, Lin Shen. Wild-type KRAS and BRAF could predict response to Cetuximab in Chinese colorectal cancer patients. Chinese Journal of Cancer Research 2011; 23(4): 271 doi: 10.1007/s11670-011-0271-4
|
| 8 |
Zhen-Hua Wang, Qin-Yan Gao, Jing-Yuan Fang. Loss of PTEN expression as a predictor of resistance to anti-EGFR monoclonal therapy in metastatic colorectal cancer: evidence from retrospective studies. Cancer Chemotherapy and Pharmacology 2012; 69(6): 1647 doi: 10.1007/s00280-012-1886-y
|
| 9 |
Jihye Yun, George Poulogiannis, Evan T. Brower, Samuel Klempner, Lewis L. Cantley. Molecular Pathogenesis of Colorectal Cancer. 2013; : 157 doi: 10.1007/978-1-4614-8412-7_6
|
| 10 |
Christopher Hocking, Jennifer E Hardingham, Vy Broadbridge, Joe Wrin, Amanda R Townsend, Niall Tebbutt, John Cooper, Andrew Ruszkiewicz, Chee Lee, Timothy J Price. Can we accurately report PTEN status in advanced colorectal cancer?. BMC Cancer 2014; 14(1) doi: 10.1186/1471-2407-14-128
|
| 11 |
Gang Wu, Weiyuan Huang, Junnv Xu, Wenzhu Li, Yu Wu, Qianyu Yang, Kun Liu, Mingyue Zhu, Priya S. Balasubramanian, Mengsen Li. Dynamic contrast-enhanced MRI predicts PTEN protein expression which can function as a prognostic measure of progression-free survival in NPC patients. Journal of Cancer Research and Clinical Oncology 2021; doi: 10.1007/s00432-021-03764-7
|
| 12 |
Riccardo Giampieri, Mario Scartozzi, Michela Del Prete, Elena Maccaroni, Alessandro Bittoni, Luca Faloppi, Maristella Bianconi, Luca Cecchini, Stefano Cascinu. Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. Critical Reviews in Oncology/Hematology 2013; 88(2): 272 doi: 10.1016/j.critrevonc.2013.05.008
|
| 13 |
Alexander Picker, David B Jackson. Genetic determinants of anticancer drug activity: towards a global approach to personalized cancer medicine. Expert Review of Molecular Diagnostics 2011; 11(6): 567 doi: 10.1586/erm.11.45
|
| 14 |
Geraldine Perkins, Camilla Pilati, Helene Blons, Pierre Laurent-Puig. Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer. Pharmacogenomics 2014; 15(7): 1043 doi: 10.2217/pgs.14.66
|
| 15 |
Bingjun Bai, Lina Shan, Binbin Xie, Xuefeng Huang, Weifang Mao, Xiaowei Wang, Da Wang, Hongbo Zhu. Mutations in KRAS codon 12 predict poor survival in Chinese patients with metastatic colorectal cancer. Oncology Letters 2017; doi: 10.3892/ol.2017.7709
|